Selectin Antagonists
Tóm tắt
Asthma and COPD are chronic inflammatory conditions that affect hundreds of millions of patients worldwide. New therapeutics are desperately needed, especially those that target the underlying causes and prevent disease progression. Although asthma and COPD have distinct etiologies, both are associated with reduced airflow caused by excess infiltration of inflammatory cells into healthy lung tissues. As selectin-mediated adhesion of leukocytes to the vascular endothelium is a key early event in the initiation of the inflammatory response, selectin inhibition is thought to be a good target for therapeutic intervention. Three known selectins are expressed in distinct subsets of cells: P-selectin is presented on the surface of activated platelets and endothelial cells, L-selectin is constitutively expressed on leukocytes, and E-selectin synthesis is upregulated in activated endothelial cells. They mediate cell-cell adhesion in the shear flow of the bloodstream via specialized interactions with clusters of oligosaccharides presented on cell surface glycopeptide ligands. The role of selectin-ligand interactions in the inflammatory response has been demonstrated in various animal models, prompting considerable attention from the pharmaceutical industry. Drug discovery efforts have yielded many different classes of selectin inhibitors, including soluble protein ligands, antibodies, oligosaccharides and small molecules. Although many selectin inhibitors have shown activity in preclinical models, clinical progress of selectin-directed therapies has been slow. Early approaches employed carbohydrate-based inhibitors to mimic the natural ligand sialyl Lewis X; however, these compounds proved challenging to develop. Cytel’s CY 1503, a complex oligosaccharide, progressed to phase II/III trials for reperfusion injury, but further development was halted when it failed to demonstrate clinical efficacy. Two protein-based selectin inhibitors have reached phase II development. These included Wyeth’s recombinant soluble P-selectin ligand, TSI (PSGL-1), which was discontinued after disappointing results in myocardial infarction trials and Protein Design Labs’ humanized anti-L-selectin monoclonal antibody, which is currently in development for trauma. Bimosiamose, discovered by Encysive Pharmaceutical and presently being developed by Revotar Biopharmaceuticals, is an 863 g/mol molecular weight dimer with minimal carbohydrate content and is, to date, the leading selectin inhibitor in clinical development. This compound has shown promise in a phase Ha ‘proof of concept’ trial in patients with asthma, reducing airway recruitment of eosinophils after intravenous administration. Further clinical development of an inhaled formulation is underway. Despite a significant need for new therapeutics, selectin inhibitors have not yet been explored for the treatment of COPD. Bimosiamose represents an important proof of principle, and hopefully continued success will spark renewed interest in selectin-directed therapeutics for respiratory diseases.
Tài liệu tham khảo
World Health Organization. World Health Report 1998. Life in the 21st century: a vision for all. Geneva: World Health Organization, 1998
News and commentary: fighting for breathing space in the respiratory market [news article]. Curr Drug Disc 2002 Jul: 10–l
Schleimer RP, Bochner BS. The role of adhesion molecules in allergic inflammation and their suitability as targets of antiallergic therapy. Clin Exp Allergy 1998; 28Suppl. 3: 15–23
Vanderslice P, Biediger RJ, Woodside DG, et al. Development of cell adhesion molecule antabonists as therapeutics for asthma and COPD. Pulm Pharmacol Ther 2004; 17(1): 1–10
Albelda SM, Smith CW, Ward PA. Adhesion molecules and inflammatory injury. FASEB J 1994; 8: 504–12
Romano SJ, Slee DH. Targeting selectins for the treatment of respiratory diseases. Curr Opin Investig Drugs 2001; 2(7): 907–13
Vestweber D, Blanks J. Mechanisms that regulate the function of the selectins and their ligands. Physiol Rev 1999; 79(1): 181–213
Lowe JB, Ward PA. Therapeutic inhibition of carbohydrate-protein interactions in vivo. J Clin Invest 1997; 99(5): 822–6
McEver R. Selectins. Curr Opin Immunol 1994; 6(1): 75–84
McEver RP, Moore KL, Cummings RD. Leukocyte trafficking mediated by selectin-carbohydrate interactions. J Biol Chem 1995; 270(19): 11025–8
Tedder TF, Steeber DA, Chen A, et al. The selectins: vascular adhesion molecules. FASEB J 1995; 9(10): 866–73
Rosen SD, Bertozzi CR. The selectins and their ligands. Curr Opin Cell Biol 1994; 6(5): 663–73
Lasky L, Presta L, Erbe D. Structure-function aspects of selectin-carbohydrate interactions. In: Metcalf B, Dalton B, Poste G, editors. Cellular adhesion: molecular definition to therapeutic potential. New York: Plenum Press, 1994: 37–53
Bertozzi C. Cracking the carbohydrate code for selectin recognition. Chem Biol 1995; 2(11): 703–8
Aigner S, Sthoeger Z, Fogel M, et al. CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells. Blood 1997; 89(9): 3385–95
Lawrence M. Selectin-carbohydrate interactions in shear flow. Curr Opin Chem Biol 1999; 3(6): 659–64
Lawrence MB, Kansas GS, Kunkel EJ, et al. Threshold levels of fluid shear promote leukocyte adhesion through selectins (CD62L,P,E). J Cell Biol 1997; 136(3): 717–27
Slee D, Romano S, Yu J, et al. The development of potent non-carbohydrate imidazole-based small molecule selectin inhibitors with anti-inflammatory activity. J Med Chem 2001; 44(13): 2094–107
Ohmoto H, Nakamura K, Inoue T, et al. Studies on selectin blocker 1. structure-activity relationships of sialyl Lewis X analogs. J Med Chem 1996; 39(6): 1339–43
Foxall C, Watson SR, Dowbenko D, et al. The three members of the selectin receptor family recognize a common carbohydrate epitope, the sialyl Lewis X oligosaccharide. J Cell Biol 1992; 117(4): 895–902
Kogan TP, Dupre B, Bui H, et al. Novel synthetic inhibitors of selectin-mediated cell adhesion: synthesis of 1,6-bis[3- (3-carboxymethylphenyl)-4- (2-cc-D-mannopyranosyloxy)phenyl]hexane (TBC1269). J Med Chem 1998; 41: 1099–111
Jenison R, Jennings S, Walker D, et al. Oligonucleotide inhibitors of P-selectin-dependent neutrophil-platelet adhesion. Antisense Nucleic Acid Drug Dev 1998; 8(4): 265–79
Sanders W, Gordon E, Dwir O, et al. Inhibition of L-selectin-mediated leukocyte rolling by synthetic glycoprotein mimics. J Biol Chem 1999; 274(9): 5271–8
Reinhardt P, Kubes P. Differential leukocyte recruitment from whole blood via endothelial adhesion molecules under shear conditions. Blood 1998; 92(12): 4691–9
Sriramarao P, Anderson W, Wolitzky B, et al. Mouse bone marrow-derived mast cells roll on P-selectin under conditions of flow in vivo. Lab Invest 1996; 74(3): 634–43
Lawrence M, Springer T. Leukocytes roll on a selectin at physiologic flow rates: distinction from and prerequisite for adhesion through integrins. Cell 1991; 65(5): 859–73
Whelan J. Selectin synthesis and inflammation. Trends Biochem Sci 1996; 21(2): 65–9
Frenette P, Wagner D. Insights into selectin function from knockout mice. Thromb Haemost 1997; 78(1): 60–4
Etzioni A, Tonetti M. Leukocyte adhesion deficiency II-from A to almost Z. Immunol Rev 2000; 178: 138–47
Etzioni A, Doerschuk C, Harlan J. Of man and mouse: leukocyte and endothelial adhesion molecule deficiencies. Blood 1999; 94(10): 3281–8
von-Andrian U, Berger E, Ramezani L, et al. In vivo behavior of neutrophils from two patients with distinct inherited leukocyte adhesion deficiency syndromes. J Clin Invest 1993; 91(6): 2893–7
Price T, Ochs H, Gershoni-Baruch R, et al. In vivo neutrophil and lymphocyte function studies in a patient with leukocyte adhesion deficiency type II. Blood 1994; 84(5): 1635–9
Frenette P, Mayadas T, Rayburn H, et al. Susceptibility to infection and altered hematopoiesis in mice deficient in both P- and E-selectins. Cell 1996; 84(4): 563–74
Munoz F, Hawkins E, Bullard D, et al. Host defense against systemic infection with Streptococcus pneumoniae is impaired in E-, P-, and E/P-selectin deficient mice. J Clin Invest 1997; 100(8): 2099–106
Maly P, Thall A, Petryniak B, et al. The α (l,3)fucosyltransferase Fuc-TVII controls leukocyte trafficking through an essential role in L-, E-, and P-selectin ligand biosynthesis. Cell 1996; 86: 643–53
Berens K, Vanderslice P, Dupre B, et al. Selectin antagonists: therapeutics for airway inflammation. In: Hansel T, Barnes P, editors. New drugs for asthma, allergy and COPD. Vol. 31. Basel: Karger, 2001: 306–9
Ward P, Mulligan M, Vaporciyan A, et al. Adhesion molecules in experimental lung inflammatory injury. In: Ward P, Fantone J, editors. Adhesion molecules and the lung. Vol. 89. New York: Dekker, 1996: 159–76
Ward P, Mulligan M. Adhesion molecules in inflammatory lung injury. In: Paul L, Issekutz T, editors. Adhesion molecules in health and disease. New York: Dekker, 1997: 523–37
De Sanctis GT, Wolyniec WW, Green FHY, et al. Reduction of allergic airway responses in P-selectin-deficient mice. J Appl Physiol 1997; 83(3): 681–7
Broide D, Sullivan S, Gifford T, et al. Inhibition of pulmonary eosinophilia in P-selectin and ICAM-1-deficient mice. Am J Respir Cell Mol Biol 1998; 18(2): 218–25
Fiscus L, Herpen JV, Steeber D, et al. L-Selectin is required for the development of airway hyperresponsiveness but not airway inflammation in a murine model of asthma. J Allergy Clin Immunol 2001; 107(6): 1019–24
Tang M, Fiscus L. Important roles for L-selectin and ICAM-1 in the development of allergic airway inflammation in asthma. Pulm Pharmacol Ther 2001; 14(3): 203–10
Abraham W, Ahmed A, Sabater J, et al. Selectin blockade prevents antigen-induced late bronchial responses and airway hyperresponsiveness in allergic sheep. Am J Respir Crit Care Med 1999; 159(4): 1205–14
Gundel RH, Wegner CD, Torcellini CA, et al. Endothelial leukocyte adhesion molecule-1 mediates antigen-induced acute airway inflammation and late-phase obstruction in monkeys. J Clin Invest 1991; 88(4): 1407–11
Dasgupta F. Selectin antagonists. In: Kahn M, editor. High throughput screening for novel anti-inflammatories. Basel: Birkhauser Verlag, 2000: 123–44
Romano S, Slee D. Targeting selectins for the treatment of respiratory diseases. Curr Opin Investig Drugs 2001; 2(7): 907–13
Stewart A, Bhatia P, McCarty C, et al. Discovery of inhibitors of cell adhesion molecule expression in human endothelial cells: 1. Selective inhibition of ICAM-1 and E-selectin expression. J Med Chem 2001; 44(6): 988–1002
Bennett F, Condon T, Grimm S, et al. Inhibition of endothelial cell adhesion molecule expression with antisense oligonucleotides. J Immunol 1994; 152(7): 3530–40
Hafezi-Moghadam A, Thomas K, Prorock A, et al. L-Selectin shedding regulates leukocyte recruitment. J Exp Med 2001; 193(7): 863–72
Diaz-Gonzales F, Gonzales-Alvaro I, Campanero MR, et al. Prevention of in vitro neutrophil-endothelial attachment through shedding of L-selectin by non-ster-oidal antiinflammatory drugs. J Clin Invest 1995; 95(4): 1756–65
Tilton R, Berens K. Functional role for selectins in the pathogenesis of cerebral ischemia. Drug News Perspect 2002; 15(6): 351–7
Aydt E, Wolff G. Development of synthetic pan-selectin antagonists: a new treatment strategy for chronic inflammation in asthma. Pathobiol 2003; 70: 297–301
Schlag G, Redl H, Till G, et al. Anti-L-selectin antibody treatment of hemorrhagic- traumatic shock in baboons. Crit Care Med 1999; 27(9): 1900–7
Kumar A, Villani M, Patel U, et al. Recombinant soluble form of PSGL-1 accelerates thrombolysis and prevents reocclusion in a porcine model. Circulation 1999; 99(10): 1363–9
Ridings P, Holloway S, Bloomfield G, et al. Protective role of synthetic sialylated oligosaccharide in sepsis-induced acute lung injury. J Appl Physiol 1997; 82(2): 644–51
Park I, Lee D, Song M, et al. Cylexin: a P-selectin inhibitor prolongs heart allograft survival in hypersensitized rat recipients. Transplant Proc 1998; 30(7): 2927–8
Alper J. Searching for medicine’s sweet spot. Science 2001; 291: 2338–43
Cytel Corporation halts clinical trial of Cylexin [company press release]. San Diego, 1999
Service R. After the fall. Science 2001; 291: 2340–1
Seekamp A, van Griensven M, Dhondt E, et al. The effect of anti-L-selectin (aseulizumab) in multiple traumatized patients: results of a phase II clinical trial. Crit Care Med 2004; 32(10): 2021–8
Lorenz HM, Kalden JR. Perspectives for TNF-a-targeting therapies. Arthritis Res 2002; 4Suppl. 3: S17–24
Graves BJ, Crowther RL, Chandran C, et al. Insight into E-selectin/ligand interaction from the crystal structure and mutagenesis of the Lec/EGF domains. Nature 1994; 367(6463): 532–8
Somers W, Tang J, Shaw G, et al. Insights into the molecular basis of leukocyte tethering and rolling revealed by structures of P- and E-selectin bound to sLex and PSGL-1. Cell 2000; 103(3): 467–79
Poppe L, Brown G, Philo J, et al. Conformation of sLex tetrasaccharide, free in solution and bound to E-, P-, and L-selectin. J Am Chem Soc 1997; 119: 1727–36
Norman K, Anderson G, Kolb HC, et al. Sialyl Lewis X (sLex) and an sLex mimetic, CGP69669A, disrupt E-selectin-dependent leukocyte rolling in vivo. Blood 1998; 91(2): 475–83
Todderud G, Nair X, Lee D, et al. BMS-190394, a selectin inhibitor, prevents rat cutaneous inflammatory reactions. J Pharmacol Exp Ther 1997; 282(3): 1298–304
Tsukida T, Moriyama H, Kurokawa K, et al. Studies on selectin blockers. 7. Structure-activity relationships of sialyl Lewis X mimetics based on modified Ser-Glu dipeptides. J Med Chem 1998; 41(22): 4279–87
Pradella L. TBC-1269: Texas Biotechnology Group. Curr Opin Anti-Inflamm Immunomod Invest Drugs 1999; 1(1): 56–60
Beeh K-M, Beier J, Buhl R, et al. Influence of inhaled bimosiamose (TBC 1269) a synthetic pan-selectin antagonist, on the allergen-induced late asthmatic response (LAR) in patients with mild allergic asthma [abstract]. Am J Resp Crit Care Med 2004; 167(7): A321
Slee D, Romano S, Yu J, et al. Development of potent non-carbohydrate small molecule selectin inhibitors. American Chemical Society 221 st National Meeting; 2001 Apr 1–5; San Diego
Romano SJ, Slee DH, John JK, et al. OC 229-648, A novel, non-carbohydrate small molecule selectin inhibitor with anti-inflammatory activity [abstract]. Inflamm Res 2000; 49Suppl. 2: S90
Douwes J, Gibson P, Pekkanen J, et al. Non-eosinophilic asthma: importance and possible mechanisms. Thorax 2002; 57(7): 643–8
Giembycz M. Are eosinophils out of asthma? Trends Pharmacol Sci 2001; 22(2): 61–2
Rogers D, Giembycz M. Asthma therapy for the 21st century. Trends Pharmacol Sci 1998; 19(5): 160–4
Adcock I, Matthews J. New drugs for asthma. Drug Discov Today 1998; 3(9): 395–9
Liebermann P. 57th AAAAI: novel drugs. IDrugs 2001; 4(6): 639–42
Paterson D. Asthma: new drug targets and innovative therapeutics. SMi Conference. IDrugs 2001; 4(6): 646–9
Henderson WJ, Chi E, Albert R, et al. Blockade of CD49d (α4 integrin) on intrapulmonary but not circulating leukocytes inhibits airway inflammation and hyperresponsiveness in a mouse model of asthma. J Clin Invest 1997; 100(12): 3083–92
Texas Biotechnology Corp. Annual report. Houston (TX): Texas Biotechnology Corp., 1999
Hoyert D, Arias E, Smith B, et al. Deaths: final data for 1999. Natl Vital Stat Rep 2001; 49(8): 1–114
Vyas B. Severe asthma and COPD: the good, the bad and the ugly. IDrugs 2001; 4(9): 1002–4
Chavannes N, Schayck CV. Developments in the treatment of chronic obstructive pulmonary disease: the clinical picture. Curr Opin Investig Drugs 2000; 1(1): 75–8
Barnes P. New treatments for COPD. Nat Rev Drug Discov 2002; 1(6): 437–46
Barnes P. Mechanisms in COPD: differences from asthma. Chest 2000; 117 (2 Suppl.): 10S–4S
Mulligan M, Paulson J, DeFrees S, et al. Protective effects of oligosaccharides in P-selectin-dependent lung injury. Nature 1993; 364(6433): 149–51
Mulligan M, Watson S, Fennie C, et al. Protective effects of selectin chimeras in neutrophil-mediated lung injury. J Immunol 1993; 151(11): 6410–7
DiStefano A, Maestrelli P, Roggeri A, et al. Upregulation of adhesion molecules in the bronchial mucosa of subjects with chronic obstructive bronchitis. Am J Respir Crit Care Med 1994; 149 (3 Pt 1): 803–10
Witt C, Schumacher A, Liebers U, et al. Comparative analysis of P-selectin glycoprotein ligand-1 (PSGL-1) expression on leukocytes from patients with allergic asthma, COPD, and smokers [abstract]. Am J Resp Crit Care Med 2004; 169(7): A840
Davenpeck K, Berens K, Dixon R, et al. Inhibition of adhesion of human neutrophils and eosinophils to P-selectin by the sialyl Lewis antagonist TBC1269: preferential activity against neutrophil adhesion in vitro. J Allergy Clin Immunol 2000; 105(4): 769–75
Everts M, Kok R, Asgeirsdottir S, et al. Selective intracellular delivery of dexamethasone into activated endothelial cells using an E-selectin-directed immunoconjugate. J Immunol 2002; 168(2): 883–9